全文获取类型
收费全文 | 92118篇 |
免费 | 6190篇 |
国内免费 | 3135篇 |
专业分类
耳鼻咽喉 | 663篇 |
儿科学 | 2417篇 |
妇产科学 | 2297篇 |
基础医学 | 7538篇 |
口腔科学 | 2358篇 |
临床医学 | 9091篇 |
内科学 | 15181篇 |
皮肤病学 | 930篇 |
神经病学 | 3954篇 |
特种医学 | 4039篇 |
外科学 | 7418篇 |
综合类 | 15679篇 |
现状与发展 | 1篇 |
一般理论 | 17篇 |
预防医学 | 11511篇 |
眼科学 | 1951篇 |
药学 | 6681篇 |
4篇 | |
中国医学 | 5226篇 |
肿瘤学 | 4487篇 |
出版年
2023年 | 576篇 |
2022年 | 357篇 |
2021年 | 910篇 |
2020年 | 827篇 |
2019年 | 551篇 |
2018年 | 1172篇 |
2017年 | 1104篇 |
2016年 | 1241篇 |
2015年 | 1271篇 |
2014年 | 1608篇 |
2013年 | 2091篇 |
2012年 | 2845篇 |
2011年 | 5903篇 |
2010年 | 3672篇 |
2009年 | 2676篇 |
2008年 | 3474篇 |
2007年 | 3224篇 |
2006年 | 3131篇 |
2005年 | 4200篇 |
2004年 | 9016篇 |
2003年 | 8315篇 |
2002年 | 6591篇 |
2001年 | 5432篇 |
2000年 | 3312篇 |
1999年 | 3909篇 |
1998年 | 2754篇 |
1997年 | 2435篇 |
1996年 | 1580篇 |
1995年 | 1397篇 |
1994年 | 1471篇 |
1993年 | 2066篇 |
1992年 | 1916篇 |
1991年 | 1703篇 |
1990年 | 1398篇 |
1989年 | 1130篇 |
1988年 | 880篇 |
1987年 | 781篇 |
1986年 | 735篇 |
1985年 | 485篇 |
1984年 | 307篇 |
1983年 | 219篇 |
1982年 | 165篇 |
1981年 | 153篇 |
1980年 | 134篇 |
1979年 | 212篇 |
1978年 | 165篇 |
1977年 | 137篇 |
1975年 | 140篇 |
1974年 | 163篇 |
1973年 | 143篇 |
排序方式: 共有10000条查询结果,搜索用时 246 毫秒
21.
Journal of Chinese Pharmaceutical Sciences 《中国药学》2020,29(12):829-831
A biography of Academician Zhicen Lou. 相似文献
22.
23.
目的:研究Visumax飞秒激光辅助的准分子激光原位角膜磨镶术(LASIK)术中不透明气泡层(OBL)产生的类型、相关影响因素及其临床意义。方法:回顾性分析。收集2016 年7 月1 日至8 月20 日在南京医科大学附属眼科医院行飞秒LASIK的患者154 例(300 眼)的临床资料,等效球镜度为(-5.88±1.51)D。飞秒激光采用Zeiss公司 Visumax飞秒激光仪,将术中产生的OBL分为瓣外OBL、瓣内快速OBL和瓣内慢速OBL。300 眼按角膜曲率平均K值分为A组(<42 D)、B组(42~46 D)和C组(>46 D);按角膜瓣的厚度分为D组(100 μm)、E组(110 μm)和F组(120 μm);按角膜厚度分为G组(<500 μm)、H组(500~540 μm)和I组(>540 μm)。统计不同角膜曲率、角膜瓣厚度、角膜厚度情况下3 种OBL产生的比例,并采用多元Logistic回归模型进行统计分析。结果:300 眼均发生OBL。以瓣外OBL作为参照,角膜瓣越薄,越容易出现瓣内快速OBL(r=-0.719,P=0.034)和瓣内慢速OBL(r=-0.875,P=0.044)。以瓣内慢速OBL作为参照,角膜曲率越高,越容易出现瓣内快速OBL(r=0.923,P=0.046);角膜瓣越厚,越容易出现瓣外OBL(r=0.897,P=0.044)。结论:OBL的产生与角膜曲率、角膜瓣厚度、角膜厚度均存在一定的相关性,但瓣外OBL、瓣内快速OBL和瓣内慢速OBL对Visumax飞秒激光辅助的LASIK术后视觉质量的影响及远期疗效仍有待进一步观察研究。 相似文献
24.
25.
26.
Sandrine Hild MD MPH Marion Johanet MD Anna Valenza MD Maïna Thabaud MD Flore Laforest MD MPH Emilie Ferrat MD PhD Cédric Rat MD PhD for the DEDICACES Group the French National College of General Practitioners 《Cancer》2020,126(12):2765-2774
Mammographic screening contributes to a reduction in specific mortality, but it has disadvantages. Decision aids are tools designed to support people's decisions. Because these aids influence patient choice, their quality is crucial. The objective of the current study was to conduct a systematic review of decision aids developed for women eligible for mammographic screening who have an average breast cancer risk and to assess the quality of these aids. The systematic review included articles published between January 1, 1997, and August 1, 2019, in the PubMed, Embase, Cochrane, and PsycInfo databases. The studies were reviewed independently by 2 reviewers. Any study containing a decision aid for women eligible for mammographic screening with an average breast cancer risk was included. Two double-blind reviewers assessed the quality of the selected decision aids using the International Patient Decision Aid Standards instrument, version 3 (IPDASi). Twenty-three decision aids were extracted. Classification of decision aid quality using the IPDASi demonstrated large variations among the decision aids (maximum IPDASi score, 188; mean ± SD score, 132.6 ± 23.8; range, 85-172). Three decision aids had high overall scores. The 3 best-rated dimensions were disclosure (maximum score, 8; mean score, 6.8), focusing on transparency; information (maximum score, 32; mean score, 26.1), focusing on the provision of sufficient details; and probabilities (maximum score, 32; mean score 25), focusing on the presentation of probabilities. The 3 lowest-rated dimensions were decision support technology evaluation (maximum score, 8; mean score, 4.3), focusing on the effectiveness of the decision aid; development (maximum score, 24; mean score, 12.6), evaluating the development process; and plain language (maximum score, 4; mean score, 1.9), assessing appropriateness for patients with low literacy. The results of this review identified 3 high-quality decision aids for breast cancer screening. 相似文献
27.
28.
Akihisa Hidaka Norie Sawada Thomas Svensson Atsushi Goto Taiki Yamaji Taichi Shimazu Motoki Iwasaki Manami Inoue Shoichiro Tsugane for the JPHC Study Group 《International journal of cancer. Journal international du cancer》2020,147(2):331-337
Family history (FH) of cancer is an important factor of increased risk of several cancers. Although the association between FH of cancer and concordant cancer risk has been reported in many previous epidemiological studies, no comprehensive prospective study with adjustment for lifestyle habits has evaluated the association of FH of cancer and concordant cancer risk. We investigated the association between FH of cancer and concordant cancer risk in a Japanese population-based prospective study, initiated in 1990 for cohort I and in 1993 for cohort II. We analyzed data on 103,707 eligible subjects without a history of cancer who responded to a self-administered questionnaire including FH of cancer at baseline. Study subjects were followed through 2012 and analyzed using multivariable-adjusted Cox proportional hazards regression models. During 1,802,581 person-years of follow-up, a total of 16,336 newly diagnosed cancers were identified. Any site (Hazard ratios = 1.11 (95% confidence interval = 1.07–1.15]), esophagus (2.11 [1.00–4.45]), stomach (1.36 [1.19–1.55]), liver (1.69 [1.10–2.61]), pancreas (2.63 [1.45–4.79]), lung (1.51 [1.14–2.00]), uterus (1.93 [1.06–3.51]) and bladder cancers (6.06 [2.49–14.74]) with FH of the concordant cancer were associated with an increased risk compared to those without FH. Our findings suggest that having FH of cancer is associated with an increased risk of several concordant cancer incidences in an Asian population. Enquiring about FH of several types of cancer may be important in identifying groups at high-risk of those cancers. 相似文献
29.
国家癌症中心/国家肿瘤质控中心 《中华放射肿瘤学杂志》2020,29(10):813-821
螺旋断层治疗系统(HT)是一种集调强放射治疗和影像引导放射治疗于一体的放射治疗系统,是目前最先进的放疗设备之一。考虑其与常规直线加速器质量保证的差异,由国家癌症中心/国家肿瘤质控中心提出,多家医疗单位共同参与制定了本指南。指南包括国内医疗机构HT用于临床工作的验收项目、操作制度、应急预案等内容,明确了质量控制的测试方法、评价标准、检测频率。指南结合国内医疗单位实际情况给出了推荐性检测项目,主要包括机械精度、剂量输出与分布、激光定位系统、治疗床运动精度、MVCT影像系统质控检测、临床治疗计划验证等具体实施方法步骤,使得指南具有很强的可操作性。本指南能给临床工作人员提供质量保证技术指导,使HT质量保证工作有章可循,可提高放射治疗的准确性和精度。对国内各医疗机构建立规范HT质量保证体系具有指导意义。 相似文献
30.
Fluid role boundaries: exploring the contribution of the advanced nurse practitioner to multi‐professional palliative care 下载免费PDF全文